Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Regulatory News Service
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Major Shareholding Notification
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Major Shareholding Notification
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
ISS
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
ISS
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
Interim Report
RFS
French 927.7 KB
2025-08-25 09:57
Major Shareholding Notification
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Major Shareholding Notification
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.